57 results on '"Jang M"'
Search Results
2. EE353 An Analysis of Stakeholders’ Contribution to High-WAC and Low-WAC Adalimumab Products in 2025 Under the Inflation Reduction Act in the United States
3. EE247 Budget Impact of Infliximab Subcutaneous from the US Healthcare Perspective
4. (702) - Cell-Free DNA Exposes Tissue Injury Profiles Leading to Primary Graft Dysfunction
5. (659) - Cell-Free DNA to Unveil Potential Mechanisms of Racial Disparities in Lung Transplant
6. (620) - Association of Donor-Derived Cell-Free DNA Levels with the Development of De Novo Donor-Specific Antibodies and Risk of Death in Lung Transplant Recipients
7. (201) - Cell-Free DNA Identifies High-Risk Donor Specific Antibodies in Heart Transplant Recipients
8. (59) - Myocardial Offloading with a Left Ventricular Assist Device Reduces End Organ Injury
9. (51) - A Molecular Criteria for Antibody Mediated Rejection in Lung Transplant Recipients is Associated with an Increased Risk of the Composite Outcome of CLAD and Death
10. MT54 Evolving Landscape of Oncology Biosimilars: In-Depth Interview of Stakeholders Regarding Bevacizumab and Trastuzumab Biosimilar
11. EE427 Analyzing the Impact of the Inflation Reduction Act of 2022 on Biosimilars in the United States: A Simulation with Adalimumab
12. (220) Cell-Free DNA Enhances Pathologist Interrater Reliability at the Assessment of Acute Rejection on Endomyocardial Biopsy, on Behalf of the GRAfT Investigators
13. (1207) Anellovirus: A Novel Marker for Overimmunosuppression and Risk of Infection in Lung Transplant Recipients
14. (130) Dysregulated Circulating Proteins in Cellular and Antibody-Mediated Rejection, on Behalf of the Graft Investigators
15. Down-Regulation of TGF-β and VCAM-1 Is Associated With Successful Treatment of Chronic Rejection in Rats
16. 800 Dermoscopic findings and histopathological correlation in large cell acanthoma
17. Genome-Wide Cell-Free DNA Methylation Analysis Reveals Significant Recipient Tissue Injury in Allograft Rejection
18. Absolute versus Percent of Donor-Derived Cell-Free DNA to Detect Lung Transplantation Rejection
19. Elevated Cell Free DNA in Respiratory Viral Infection and Associated Lung Allograft Dysfunction
20. Is Acute Rejection Truly Acute or an Exacerbation of an Underlying Disease?
21. Genome-Wide DNA Methylation Analysis to Define Pulmonary Antibody-Mediated Rejection (AMR) Treatment Response
22. Restrictive Allograft Syndrome Patients Have Higher Cell-Free DNA Assessed Allograft Injury Prior to Diagnosis
23. 648 Dermoscopic findings and HPV genotypes of genital keratotic lesions: Bowenoid papulosis, seborrheic keratosis, and condyloma acuminatum
24. Impact of AMR Treatment: Responders vs Non-Responders Characteristics
25. Cell-Free DNA to Monitor Immunosuppression Adequacy in Lung Transplantation
26. Increased Cell Free DNA Levels in African American Patients Early after Heart Transplantation
27. Cardiac Allograft Injury in Patients of African Ancestry: Trends of Donor-Derived Cell-Free DNA Based on Genetic Ancestry
28. Racial Differences in Immunosuppression and Lung Transplant Outcomes
29. Cell-Free DNA Tissue Damage Mapping in Transplant Patients Infected with COVID-19
30. 368 Epidemiology and clinical outcomes of 151 patients with mycosis fungoides at the Kosin University Gospel Hospital: Retrospective 27-year review
31. Outcomes of ISHLT Lung Transplant AMR
32. Early and Late Pulmonary AMR Show Distinct Profiles; Clinical and Epigenetic Analyses
33. Lung Transplantation: DSA to AMR Trajectory
34. Allograft Injury and Outcomes in African American Lung Transplant Recipients
35. Association between Pretransplant Antibody against Angiotensin II Type 1 Receptor and Posttransplant Allograft Injury
36. To Treat or Not to Treat: DSA Positive Lung Transplant Recipients
37. Donor-Derived-Cell-Free DNA to Identify Primary Graft Dysfunction Patients at Risk of Chronic Lung Allograft Dysfunction
38. P1.14 Immune Profiling Data and Mutational Status Improves Prediction of Risk of Death in Non-Small Cell Lung Carcinoma
39. Characteristics of Urine Cell-Free DNA in Heart and Lung Transplant
40. Inflammatory Events Precede Development of De Novo DSA after Lung Transplantation
41. Pulmonary Antibody-Mediated Rejection (AMR) Accelerates Aging-Evidence from Whole Genome DNA Methylation Sequencing
42. Mitochondrial DNA Mismatches in Thoracic Transplantation: Potential Triggers of Allograft Immunogenicity
43. 523 Low dose methotrexate treatment for primary cutaneous CD30+ lymphoproliferative disorders: A long-term follow-up
44. (220) - Variable Cell-free DNA Characteristics With Different Acute Rejection Phenotypes
45. (176) - Validation of Donor-derived Cell-free DNA to Detect Heart-transplant Rejection
46. (57) - Clinically-unrecognized Allograft Injury is Common After Lung Transplantion
47. (15) - Antibody-mediated Rejection: Should We Wait for Clinical Diagnosis?
48. (13) - Is the New ISHLT Criteria for Pulmonary Antibody-mediated Rejection Also a Severity Indicator?
49. PSY1 - Evaluation of Safety and Efficacy of Propofol for Procedural Sedation in Pediatric Population: A Meta-Analysis
50. PIH30 - Effects of Propofol Versus Other General Anesthesia in Children Younger Than 3 Years of Age: A Systematic Review and Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.